Dr. Kenichiro Niimi is looking forward to helping more cancer patients.
The Ministry of Health and Welfare has recently announced the draft amendment to the Administrative Measures for the Implementation or Use of Specific Medical Technology Inspection and Testing Medical Instruments (hereinafter referred to as "Special Administrative Measures"), and both autologous peripheral blood stem cell transplantation and autologous immune cell therapy, both of which are of great concern to cancer patients, have been incorporated into these Special Administrative Measures, so that after approval and registration of a medical institution, it can administer cell therapy to patients who are eligible for such treatment. In order to welcome the new era of cancer immunotherapy, the domestic academic and biotech industries have joined forces to organize the International Symposium on Cancer Cellular Immunotherapy, and invited Dr. Kenichiro Renmi, a leading Japanese immunotherapy authority, to share his patented HITV (Human Initiated Therapeutic Vaccine) therapy for cancer immunotherapy in Taiwan.
Officials, industry, and academia join forces to open a new era of cancer immunocellular therapy
Currently, the principle of immunotherapy can be divided into two categories, the first is to strengthen the effectiveness of the own immune system to fight against foreign viruses, bacteria, or abnormal cells, such as cancerous cells, from the body's own initiative, and the second is to send foreign antibodies or domesticated cells into the body, so that the body's immune system recognizes that the body's immune system has been damaged by these antibodies. The second is to send foreign antibodies or domesticated cells into the body, so that the body's immune system recognizes the markers of these foreign substances and enhances the recognition and elimination of cancer cells, and immunotherapy is developed according to these two principles. In addition, it is also important to note that the use of the Internet is not only a way for people to access the Internet, but it is also a way for them to access the Internet without the need for a computer, so that they can access the Internet without the need for a computer.
Returning to individualized anticancer treatment using one's own "immunity"
Through the regulation of one's own immunity, the treatment is not as extensive as chemotherapy or targeted drugs, but the immunotherapy is more accurate in the identification of the cancer cells, and it is based on one's own immune system, which makes it possible for the patient to be excluded from the treatment. Immunotherapy is more accurate in recognizing cancer cells and is based on the immune system, which results in less rejection and fewer side effects, and more and more studies are turning to immunotherapy. Kenichiro Hasami developed HITV therapy in 2005, which uses antigens from one's own cancer cells to train dendritic cells (DCs) in the immune system to become a special force, and then passes these skills of recognizing cancer cells to cytotoxic T cells (CTLs) that have the function of killing, and then these killer immune cells can quickly and accurately recognize cancer cells in the body. These killer immune cells can then quickly and accurately recognize the cancer cells in the body and completely target and kill them.
HITV In combination with chemotherapy and radiotherapy, HITV can enhance immunity to eliminate tumors and prevent recurrence
The combination of HITV and chemotherapy makes the effect of HITV even more promising. In HITV therapy, there is also a part that combines radiotherapy and chemotherapy, which utilizes IMRT to precisely control the direction and intensity of irradiation to minimize the damage to normal cells, while chemotherapy uses patented "molecular markers" and other medications to identify proliferating and metastatic molecules that are unique to cancer cells as the target. In addition, the CTL cells induced by HITV, after fighting with cancer cells in the body, will continue to pass on this cancer-killing skill in the body, forming a huge message transmission network, shaping the body into a high immunity environment, reducing the chance of recurrence and prolonging the remission period. Dr. Lianmi is looking forward to introducing this technology to Taiwan now to help more cancer patients.
LINE@ ID:@ Subscribe to the Healthy Love LOHAS Audio/Video channel to read health knowledge more easily : /beauty/article/39009 Keywords: Cancer, Immunotherapy, Kenichiro Hasumi, Cellular Therapy, HITV Therapy, Specialty Approaches